Disclosed are methods of treating olfactory dysfunction by periodically administering a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to a subject.

Disclosed are formulations of rasagiline base which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. Also disclosed are rasagiline citrate salt and the use and process of manufacture thereof.

Nilotinib salts and crystalline forms thereof have been prepared and characterized.

Nilotinib salts and crystalline forms thereof have been prepared and characterized.

The present invention provides extended release pharmaceutical compositions of a beta blocker such as but not limited to metoprolol succinate as the active ingredient and methods of preparing such extended release pharmaceutical compositions.

Provided is a crystalline rosuvastatin intermediate and processes for preparation thereof.

The present invention provides extended release pharmaceutical compositions comprising Zolpidem or a salt thereof.

The present invention provides amorphous and crystalline forms of olanzapine pamoate and processes for preparing them. The invention further provides a pharmaceutical composition comprising at least one of the described crystalline forms of olanzapine pamoate. This pharmaceutical composition may additionally comprise at least one pharmaceutically acceptable excipient. The present invention encompasses the use of at least one of the forms of olanzapine pamoate for the preparation of a formulation...

Crystalline forms of Sitagliptin salts processes for preparing crystalline forms of Sitagliptin salts and pharmaceutical compositions of Sitagliptin salts are provided.